LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

LLY

1,115.8

+0.57%↑

JNJ

241.13

+0.72%↑

ABBV

234.57

-0.1%↓

UNH

405.65

-0.9%↓

MRK

120.63

+0.84%↑

Search

Amgen Inc

Закрыт

СекторЗдравоохранение

356.74 1.24

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

344.71

Макс.

354.3

Ключевые показатели

By Trading Economics

Доход

486M

1.8B

Продажи

-1.3B

8.6B

P/E

Средняя по отрасли

23.989

50.958

Прибыль на акцию

5.15

Дивидендная доходность

2.86

Рентабельность продаж

21.107

Сотрудники

31,500

EBITDA

-1.2B

3.9B

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+1.69% upside

Дивиденды

By Acuity

Дивидендная доходность

Средняя по отрасли

2.86%

2.41%

Следующий отчет о доходах

4 авг. 2026 г.

Дата следующей выплаты дивидендов

11 сент. 2026 г.

Следующая эксдивидендная дата

21 авг. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

2.7B

186B

Предыдущая цена открытия

355.5

Предыдущая цена закрытия

356.74

Новостные настроения

By Acuity

36%

64%

104 / 342 Рейтинг в Healthcare

Amgen Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

24 июн. 2026 г., 23:01 UTC

Amgen Inc shares are lower in after-market hours, continuing a decline since Wednesday's close. No specific news was identified to explain the movement.

23 июн. 2026 г., 20:06 UTC

Amgen Inc shares are higher since Monday's close, reaching a session high earlier today. No specific company news was identified to explain the movement.

22 июн. 2026 г., 19:33 UTC

Biotechnology stocks support Amgen Inc's upward momentum today, with shares higher since Thursday's close despite pulling back from a session high.

18 июн. 2026 г., 22:06 UTC

Amgen Inc. shares are higher in after-market trading after notable volatility, contrasting with four consecutive lower closes. No specific news was identified for the move.

17 июн. 2026 г., 19:53 UTC

Macro Event

Amgen Inc. shares are lower today, continuing a trend of declines amid the Federal Reserve's decision to hold interest rates steady.

16 июн. 2026 г., 19:22 UTC

News

Amgen shares are lower following a jury ruling on patent infringement, despite positive Phase 3 data for Repatha and European approval for Imdylltra.

15 июн. 2026 г., 21:09 UTC

Amgen Inc shares are trading higher in after-market hours. The broader market is gaining, driven by positive sentiment towards technology stocks and favorable geopolitical news.

12 июн. 2026 г., 19:51 UTC

News

Amgen Inc. is reassessing data on Tavneos amid FDA scrutiny. Shares are higher as the company challenges the proposal to withdraw the drug's approval.

11 июн. 2026 г., 23:06 UTC

News

Amgen engages Duke Clinical Research Institute to reassess Tavneos data amid FDA concerns, with shares trading higher in after-market hours.

10 июн. 2026 г., 23:51 UTC

Amgen Inc. shares declined in after-market trading, continuing a trend of lower daily closes amid rising Treasury yields and weakness in technology stocks.

9 июн. 2026 г., 19:56 UTC

News

Amgen Inc. shares are lower as Goldman Sachs cuts its price target to $389 from $425 amid an IRS audit disclosure affecting financial outlook.

8 июн. 2026 г., 20:06 UTC

News

Amgen Inc. shares are lower today after presenting Phase 3 trial results showing Repatha's effectiveness in reducing cardiovascular event risk in high-risk diabetes patients.

5 июн. 2026 г., 23:01 UTC

Amgen Inc shares are lower in after-market trading amid a broader equity sell-off following stronger-than-expected U.S. non-farm payroll data.

4 июн. 2026 г., 23:51 UTC

News

Amgen will present at the Goldman Sachs Global Healthcare Conference on June 9, 2026. Shares are trading higher in after-market hours.

3 июн. 2026 г., 23:41 UTC

Amgen Inc shares are higher in after-market trading, supported by gains in the Biotechnology sub-sector and strong performance above its 20-day moving average.

2 июн. 2026 г., 23:02 UTC

Amgen Inc. shares are lower in after-market trading, continuing a trend of declines over the last three sessions and remaining below the 20-day moving average.

1 июн. 2026 г., 20:02 UTC

Amgen Inc. shares are lower today, dropping below Friday's close and nearing the lower end of their one-month trading range. No specific news was identified.

29 мая 2026 г., 20:06 UTC

Amgen Inc's shares are higher today, reflecting a slight gain since Thursday's close. The stock remains stable within its one-month trading range.

28 мая 2026 г., 23:56 UTC

Amgen Inc's shares are higher in after-market hours, maintaining stability above the 20-day moving average and within the one-month trading range.

27 мая 2026 г., 23:01 UTC

Amgen Inc shares are higher in after-market trading, influenced by broader market dynamics, including declining US Treasury yields and inflation concerns.

26 мая 2026 г., 19:56 UTC

News

Amgen Inc. shares are lower as rising bond yields reflect inflationary pressures. Analysts maintain a positive outlook on the company's drug pipeline and capital allocation.

22 мая 2026 г., 20:06 UTC

News

Amgen Inc. is trading higher amid scrutiny of its rare disease therapy, Tavneos, linked to patient deaths and regulatory restrictions on new prescriptions.

21 мая 2026 г., 19:13 UTC

News

Amgen Inc shares rose after Japan allowed new prescriptions for a rare-disease drug, reversing a previous recommendation linked to reported deaths.

20 мая 2026 г., 19:51 UTC

News

Amgen Inc. shares are higher following the appointment of Thomas Dittrich as CFO and strong revenue growth of 12.3% over the past two years.

19 мая 2026 г., 20:03 UTC

News
Social Media

Amgen Inc. shares are trading higher as analysts express optimism about revenue growth through 2027, despite a price target reduction to $427.

18 мая 2026 г., 19:52 UTC

Social Media
News

Amgen Inc shares are lower as safety concerns over Tavneos intensify. Kissei Pharmaceutical advised caution after reports of 20 deaths linked to the drug.

15 мая 2026 г., 23:26 UTC

Social Media

Amgen Inc shares are higher in after-market trading, despite social media concerns over recent decisions and a warning from Kissei Pharmaceutical regarding a rare drug.

14 мая 2026 г., 19:16 UTC

News

Amgen shares are lower as Piper Sandler cuts price target to $427 from $432. The stock is trading within its one-month range.

13 мая 2026 г., 23:02 UTC

Amgen Inc. shares are trading lower in after-market hours, following unusual activity earlier in the session and remaining below the 20-day moving average.

Сравнение c конкурентами

Изменение цены

Amgen Inc Прогноз

Целевая цена

By TipRanks

1.69% рост

Прогноз на 12 месяцев

Средняя 357.38 USD  1.69%

Максимум 427 USD

Минимум 300 USD

Основано на мнении 24 аналитиков Wall Street, спрогнозировавших целевые цены для Amgen Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

24 ratings

10

Покупка

13

Удержание

1

Продажа

Настроения

By Acuity

104 / 342Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Ниже среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Amgen Inc

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
help-icon Live chat